ArticleDiscover oncology2025
Integrating differential gene expression and Mendelian randomization analyses reveal novel gene for prognosis, immune response, and drug sensitivity in lung cancer.
Article in Discover oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
objectiveTo integrate transcriptomic and genomic data to identify lung cancer biomarkers, evaluate their prognostic significance, and explore their potential in guiding personalized therapy.
methodWe integrated transcriptomic and genomic data to uncover genes associated with lung cancer risk using differential expression and Mendelian randomization (MR) analyses. Gene expression profiles from three GEO datasets (GSE19804, GSE18842, GSE19188) were batch-corrected with ComBat and analyzed to identify differentially expressed genes (DEGs). Two-sample MR was performed using lung cancer GWAS summary statistics. Functional enrichment, immune infiltration, survival analysis, and drug sensitivity prediction were conducted. The results were validated using The Cancer Genome Atlas (TCGA) lung cancer cohort.
resultA total of 1,193 DEGs (409 upregulated, 784 downregulated) were detected between examined groups. MR analysis revealed 253 genes associated with lung cancer risk, including 118 increasing and 135 decreasing genes. Eleven genes overlapped between DEGs and MR results, with SAPCD2 and SPP1 being found to be associated with increased risk of lung cancer, whereas GPX3, C1orf162, CTSW, TPSAB1, CD93, HK3, TFPI, NEBL, and STEAP4 exhibiting inverse association. Enrichment analysis highlighted functions in vesicle lumen, carbohydrate metabolism, and immune processes. SAPCD2 and SPP1 were correlated with pro-tumor immune infiltration. Seven genes were associated with overall survival, and a derived prognostic score effectively stratified patients and correlated with TIDE and drug response profiles.
conclusionThis integrative genomic-transcriptomic analysis uncovered genes with suggestive causal and prognostic relevance in lung cancer, emphasizing their immune roles and therapeutic potential. These insights advance the understanding of lung cancer biology and support precision oncology strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.